Synthetic protein targets EBV

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
NHE
Volunteer Moderator
Posts: 6427
Joined: Sat Nov 20, 2004 3:00 pm
Contact:
Contact NHE

Synthetic protein targets EBV

Post by NHE »

UW researchers at the Institute of Protein Design have developed a synthetic protein called BINDI which binds to the Epstein-Barr Virus (EBV) protein BHRF1 responsible for immortalizing cells. Inhibition of BHRF1, a BCL2 homologue, may prove to be a useful treatment for EBV related cancers and other conditions stemming from EBV.

http://www.ipd.uw.edu/designer-proteins ... cer-cells/

http://www.cell.com/cell/abstract/S0092 ... %2900613-8
Top
Post Reply

Return to “Drug Pipeline”